The Cancer Cell Signaling (SIG) program seeks to stimulate and facilitate fundamental research in mechanisms of cell signaling. SIG does this through new faculty recruitment, and promoting program interactions, collaborations, and information sharing. Co-leaders of the program David L. Brautigan and Kimberly A. Kelly decide on program membership status in consultation with senior leadership, and act as advisors for faculty and mentors for fellows and students by encouraging team-based research projects, and participating in the weekly Cancer Center seminar series, student journal clubs, and programmatic research conferences. SIG is comprised of 25 members from 15 different basic science and clinical departments in the School of Medicine and School of Engineering and Applied Science, and 2 associate members. The high quality science by SIG has resulted in over 318 publications over the past 5 years, with 43% inter- programmatic and 10% intra-programmatic co-authorships. Total extramural funding for the Program exceeds $8.8M, including over $3.9 million from the National Cancer Institute (NCI) and $3.8M from other NIH institutes. Members of SIG are a valuable resource and highly collaborative, supporting activities throughout the Cancer Center, as one of the cornerstones of the UVA Cancer Center research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-26
Application #
9209276
Study Section
Special Emphasis Panel (NCI (E3)-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
26
Fiscal Year
2017
Total Cost
$27,633
Indirect Cost
$10,144
Name
University of Virginia
Department
Type
Domestic Higher Education
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications